[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"melanoma-of-skin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:melanoma-of-skin":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,65,102,126,157],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100592498","characteristics-of-adult-patients-with-melanoma-diagnosis-40-years-age-100592498",false,"NCT06994208","Characteristics of Adult Patients With Melanoma Diagnosis \u003C40 Years Age.","Demographic, Clinical, Dermoscopic, Phenotypic and Genetic Characteristics of Adult Patients With Melanoma Diagnosis \u003C40 Years Age. A Prospective, Monocentric Observational Study","MELA_2025","Inclusion Criteria:\n\n1. written informed consent\n2. age \\> 18 years and \\\u003C 40 years\n3. diagnosis of cutaneous melanoma even non-primary\n\nExclusion Criteria:\n\n\\-","ALL","18 Years","39 Years",{"count":21,"type":22},25,"ESTIMATED","1 Year","OBSERVATIONAL","The primary objective of the study is to analyse a local cohort of patients aged 18-39 years with melanoma diagnosis in order to determine the prevalence of the disease in this age group.\n\nSecondary objectives are the following:\n\n* To identify risk factors associated with melanoma in young people.\n* To characterise the phenotype and dermoscopic features of melanoma in patients aged 18-39 years.\n* To analyse the relationship between the clinical and histopathological features of melanoma in young people.\n* To identify the mutational status of B-RAF in the sample of patients analysed.",[27],"Melanoma of Skin","RECRUITING","2025-12-18",{"date":31,"type":32},"2025-12-19","ACTUAL",{"date":34,"type":32},"2025-12-02",{"date":36,"type":22},"2028-08-31",{"name":38,"class":39},"Ente Ospedaliero Ospedali Galliera","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":24,"phases":4,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100595390","apa-adapted-physical-activity-for-patients-with-advanced-melanoma-100595390","NCT07031830","APA (Adapted Physical Activity) for Patients With Advanced Melanoma","APA (Adapted Physical Activity) for Patients With Advanced Melanoma APA (Adapted Physical Activity) for Patients With Advanced Melanoma Undergoing Treatment: Evaluation of a Personalized Program at the Hospital","APA-M","Inclusion Criteria:\n\n* Male or female patient aged 18 or older\n* Advanced melanoma treated adjuvantly or curatively with immunotherapy or targeted therapy\n* Patient who has read and understood the information letter and does not object to participating in the study\n* Member of or beneficiary of a social security scheme\n* Patients who have agreed to participate in the adapted sports module\n\nExclusion Criteria:\n\n* Minor patient\n* Melanoma not requiring systemic treatment\n* Condition making 6-month follow-up impossible\n* Protected incapacitated persons (judicial protection, guardianship, curatorship, deprivation of liberty)",{"count":50,"type":22},50,"24 Months","APA (adapted physical activity) for patients with advanced melanoma APA (adapted physical activity) for patients with advanced melanoma undergoing treatment: evaluation of a personalized program at the hospital Melanoma is a malignant tumor developed from melanocytes. It accounts for approximately 4% of all incident cancers and 1.2% of cancer deaths, regardless of sex.\n\nSince 2011, the advent of new therapies (targeted therapies and immunotherapies) has revolutionized the management of advanced-stage melanoma (unresectable stage III or stage IV).\n\nThese treatments have led to a significant improvement in the prognosis of metastatic melanoma, with a 5-year overall survival rate of 34% for targeted therapies, 44% for monotherapy with immunotherapy, and 52% for the combination of nivolumab + ipilimumab.\n\nDue to the improvement in survival rates, advanced melanoma has become a chronic disease affecting all ages. It is therefore essential to maintain the quality of life for these patients.",[27],[55],"adapted physical activity","2025-06-12",{"date":58,"type":32},"2025-06-22",{"date":60,"type":32},"2024-11-18",{"date":62,"type":22},"2029-01-02",{"name":64,"class":39},"University Hospital, Rouen",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100590270","phase-2-perioperative-toripalimab-and-endostatin-for-stage-ii-melanoma-a-phase-ii-trial-100590270","NCT06965231","Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial","Efficacy and Safety of Perioperative Toripalimab Combined With Recombinant Human Endostatin as Postoperative Adjuvant Therapy for Clinical Stage II Malignant Melanoma: A Multicenter, Single-Arm, Phase II Clinical Study","FUMS-EDJS2024","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of gender;\n2. ECOG performance status: 0-1;\n3. Patients with histologically or cytologically confirmed cutaneous or acral malignant melanoma, excluding mucosal and uveal melanoma;\n4. Patients with BRAF, CKIT, and NRAS gene test results;\n5. Treatment-naïve patients who have not received prior anti-tumor therapy;\n6. Clinical stage II (AJCC 8th edition, 2017);\n7. Laboratory tests must meet the following criteria:\n\n   1. Hematology: Hemoglobin (Hb) ≥90 g\u002FL (no transfusion within 14 days); absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL; platelet count (PLT) ≥100×10\\^9\u002FL;\n   2. Biochemistry: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; total bilirubin (TBIL) ≤1.5×ULN; serum creatinine (Cr) ≤1.5×ULN, and creatinine clearance \\>50 μmol\u002FL;\n   3. Coagulation: Activated partial thromboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT) ≤1.5×ULN;\n   4. Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥50%;\n8. Female patients must agree to use contraception (e.g., intrauterine device \\[IUD\\], oral contraceptives, or condoms) during the study and for 6 months after study completion. A negative serum or urine pregnancy test within 7 days before enrollment is required, and patients must be non-lactating. Male patients must agree to use contraception during the study and for 6 months after study completion;\n9. Patients must voluntarily participate in the study, sign the informed consent form, and demonstrate good compliance.\n\nExclusion Criteria:\n\n1. History of allergic reactions to biological products;\n2. Patients with prior or concurrent malignancies within 5 years (except cured basal cell carcinoma of skin or carcinoma in situ of cervix);\n3. Any active autoimmune disease or history of autoimmune disorders (including but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, nephritis; asthma requiring bronchodilators for medical intervention). Exceptions include: vitiligo, psoriasis, alopecia not requiring systemic therapy, well-controlled type I diabetes, or hypothyroidism with normal thyroid function on replacement therapy;\n4. Requirement for immunosuppressive therapy using systemic or absorbable topical corticosteroids (equivalent to prednisone \\>10mg\u002Fday) within 2 weeks prior to first dose;\n5. Any history or evidence of bleeding diathesis regardless of severity; grade ≥3 bleeding events per CTCAE v5.0 within 4 weeks prior to first dose; or presence of unhealed wounds, fractures, active gastrointestinal ulcers, ulcerative colitis, tumors with active bleeding, or other conditions deemed by investigators to potentially cause gastrointestinal hemorrhage or perforation;\n6. Patients with severe and\u002For uncontrolled comorbidities including:\n\n   1. Poorly controlled hypertension (SBP ≥150 mmHg or DBP ≥90 mmHg);\n   2. Unstable angina, myocardial infarction, ≥grade 2 congestive heart failure, or arrhythmias requiring treatment (including QTc ≥480ms) within 6 months prior to first dose;\n   3. Active or uncontrolled severe infections (≥grade 2 per CTCAE);\n   4. Clinically significant liver disease including viral hepatitis (active HBV infection with HBV DNA \\>1×10³ copies\u002FmL or \\>500 IU\u002FmL; HCV infection with HCV RNA \\>1×10³ copies\u002FmL or \\>100 IU\u002FmL), decompensated liver disease, or chronic hepatitis requiring antiviral therapy;\n   5. HIV-positive status;\n   6. Poorly controlled diabetes (fasting glucose ≥grade 2 per CTCAE);\n   7. Urinalysis showing proteinuria ≥++ with 24-hour urinary protein \\>1.0 g;\n7. Administration of live vaccines within 4 weeks prior to treatment or anticipated need during study;\n8. Other conditions deemed by investigators to potentially lead to premature study termination, including: severe comorbidities (including psychiatric disorders) requiring concomitant therapy, significant laboratory abnormalities, or social\u002Ffamily factors that may compromise patient safety or data\u002Fsample collection.",{"count":74,"type":22},58,"INTERVENTIONAL",[77],"PHASE2","This is a Phase II clinical trial to evaluate the efficacy and safety of perioperative toripalimab (anti-PD-1) combined with recombinant human endostatin (Endostar) as postoperative adjuvant therapy in patients with clinical stage II cutaneous or acral malignant melanoma. The study aims to answer:\n\n1. Does this combination improve the 2-year recurrence-free survival (2y-RFS) compared to historical data?\n2. Is the treatment safe and tolerable for patients?\n\nParticipants will:\n\n1. Receive 2 cycles of toripalimab before surgery (neoadjuvant therapy).\n2. Undergo surgical removal of the tumor.\n3. Post surgery, receive toripalimab every 2 weeks + Endostar (72-hour continuous infusion every 4 weeks) for up to 6 cycles (Endostar) or 11 cycles (toripalimab).\n4. Be monitored for tumor recurrence, side effects, and survival for up to 2 years after treatment.\n\nThis is a single-arm, multicenter study involving 58 patients across several hospitals in China. Results will help determine if this combination could become a new standard adjuvant therapy for stage II melanoma.",[27,80,81],"Acral Melanoma","Stage II Melanoma",[83,84,85,86,87,88,89,90,91],"Melanoma of skin","Acral melanoma","Stage II melanoma","Toripalimab","Recombinant human endostatin (Endostar)","Perioperative immunotherapy","PD-1 inhibitor","Anti-angiogenic therapy","Phase II study","2025-05-07",{"date":94,"type":32},"2025-05-11",{"date":96,"type":32},"2025-01-01",{"date":98,"type":22},"2029-03-30",{"name":100,"class":39},"Fudan University",4,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":40},"100574943","the-study-aims-to-measure-the-metabolome-in-melanoma-patients-using-nmr-spectroscopy-and-gas-chromatography-and-to-analyse-differences-depending-on-the-course-of-the-disease-100574943","NCT06765850","The Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease.","Measurement of the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography.","Inclusion Criteria:\n\n* Current or past history of melanoma\n* Ongoing therapy or tumour aftercare at the Skin Cancer Centre at Dresden University Hospital\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* Lack of capacity to consent",{"count":110,"type":22},3000,"Prospective, single-centre study with the central question of how the metabolome from blood samples, different body fluids and tissues between patients patients with malignant melanoma in different tumour tumour stages and healthy patients and whether this is suitable for early detection of initial diagnosis, recurrence or stage shift at an early stage.\n\nThe biosamples are collected in the BioBank Dresden and used for the NMR and LC-MS analyses described here. It is planned to use the biosamples for further analyses.",[27],[114,115,116],"Melanoma","Metabolomics","NMR","2025-01-03",{"date":119,"type":32},"2025-01-09",{"date":121,"type":32},"2022-07-04",{"date":123,"type":22},"2027-06",{"name":125,"class":39},"Technische Universität Dresden",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":133,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":135,"conditions":136,"keywords":142,"overallStatus":146,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100566930","an-observational-study-using-the-lumassure-device-in-participants-undergoing-assessment-of-skin-conditions-100566930","NCT06661577","An Observational Study Using The LumAssure Device In Participants Undergoing Assessment Of Skin Conditions.","A Multi-Centre Observational Study For The Collection Of A Raman Spectral Database Using The LumAssure Device In Adult Participants Undergoing Dermatological Assessment Of Skin Conditions","Inclusion Criteria:\n\n* Able to provide informed consent\n* Male or female aged 18 years or over.\n* Willing to undergo a LumAssure device measurement on at least 1 skin condition\n* (For Standard of Care patients): are undergoing a skin examination and\u002For tissue excision by a qualified specialist\n* (For Healthy volunteers): are attending a skin check at a study clinic\n\nExclusion Criteria:\n\n* Tattoo on the skin condition to be measured\n* Skin conditions on or directly around the eye area",true,{"count":110,"type":22},"This is an observational study in adult males and females utilising skin condition measurements using the LumAssure Raman device. Data will be used to determine accuracy under the ROC curve (AUCROC) of the LumAssure device for differentiating between benign and cancerous skin conditions. The measurements will provide data which will be used to establish spectral parameters for different skin conditions. Measurements will be benchmarked against diagnoses from medical specialists, and when available confirmed with histological data.\n\nThe main question it aims to answer is :\n\nWhat is the accuracy, in terms of the area under the ROC curve (AUCROC) of the LumAssure device for differentiating between benign skin conditions and skin cancers in adult males and females? Participants include males and females aged ≥18 years who are undergoing assessment of a skin condition (a lesion or rash) by a dermatologist, general practitioner, or plastic surgeon. Participants' attending the clinics will have their skin conditions examined by a clinician. The LumAssure device will then be used to measure Raman spectra of skin conditions and marked by the clinician. The Raman measurements will be benchmarked against skin condition assessment and, where available, diagnosis by a dermatologist, general practitioner, or a plastic surgeon, and for those lesions undergoing biopsy, confirmed with histology data.",[137,138,27,139,80,140,141],"Skin Cancers - Basal Cell Carcinoma","Skin Cancers - Squamous Cell Carcinoma","Inflammatory Dermatoses","Benign Skin Nevus","Benign Skin Tumor",[143,144,145],"skin cancers","melanoma","diagnostic device","NOT_YET_RECRUITING","2024-10-24",{"date":149,"type":32},"2024-10-28",{"date":151,"type":22},"2024-12-13",{"date":153,"type":22},"2026-02-28",{"name":155,"class":39},"University of Auckland, New Zealand",2,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":168,"conditions":169,"keywords":170,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":40},"100562398","melcaya---novel-health-care-strategies-for-melanoma-in-children-adolescents-and-young-adults---work-package-3-wp3-100562398","NCT06602648","MELCAYA - Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults - Work Package 3 (WP3)","Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults. Histological, Computational, and Molecular Pathology for Improved Diagnosis. (Mol-Mel). Work Package 3 (WP3)","Mol-Mel","Inclusion Criteria:\n\n* adolescent and childhood patients (\\< 20 years) or young adults (\\< 30 years)\n* histologically confirmed diagnosis of melanoma or intermediate\u002Fambiguous melanocytic neoplasm (i.e., melanocytomas, SAMPUS, IAMPUS and MELTUMP according to WHO classification)\n\nExclusion criteria:\n\n* adult patients (\\> 30 years of age)\n* patients without histologically confirmed diagnosis of melanoma or intermediate\u002Fambiguous melanocytic neoplasm","30 Years",{"count":167,"type":22},100,"The aim of this study is to investigate a type of skin cancer, also known as melanoma, in children, adolescents, and young adults, who will be referred to as CAYA patients in this project. The need for this study arises because this disease, in CAYA patients, is still poorly understood due to its rarity in individuals under 30 years old. This often leads to difficulties in assessing its severity and, consequently, in deciding on the necessary treatments to ensure the patient\\'s recovery. The goal of this study is to examine melanoma in CAYA patients in order to gather the information needed to provide better diagnoses for affected patients and, as a result, select appropriate treatments to fight the disease and promote the patient\\'s full recovery. Additionally, the data collected will be used to create a Pan-European online platform that will allow doctors across the European Union to consult the obtained data and collaborate on particularly complex melanoma cases, always with the aim of ensuring the patient\\'s full recovery in the shortest possible time.",[27],[114,171,172,173,174],"Pediatric","Childrens","Adolescents","Young adults","2024-09-17",{"date":177,"type":32},"2024-09-19",{"date":179,"type":32},"2024-04-17",{"date":181,"type":22},"2026-11",{"name":183,"class":39},"University of Florence"]